Regeneron Down 15.5% Year to Date: How to Play the Stock?
Portfolio Pulse from
Regeneron Pharmaceuticals (REGN) has seen a 15.5% decline in its stock year-to-date, primarily due to a rapid decline in sales of its lead drug, Eylea. Despite this, Dupixent continues to perform well. Investors are advised to adopt a wait-and-watch approach.
December 13, 2024 | 3:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Regeneron's stock has declined 15.5% YTD due to falling Eylea sales, though Dupixent remains strong. Investors are advised to wait and watch.
The decline in Eylea sales is a significant factor impacting Regeneron's stock performance, leading to a 15.5% drop YTD. While Dupixent's performance is positive, it is not enough to offset the negative impact of Eylea's sales decline. The recommendation to wait and watch suggests uncertainty in the short-term recovery of the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100